{
    "2020-06-09": [
        [
            {
                "time": "2020-08-18",
                "original_text": "Lilly's 2nd Potential Coronavirus Antibody Candidate in Phase I",
                "features": {
                    "keywords": [
                        "Lilly",
                        "Coronavirus",
                        "Antibody",
                        "Phase I"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2020-09-15",
                "original_text": "EXPLAINER-What are antibody therapies and who is developing them for COVID-19?",
                "features": {
                    "keywords": [
                        "antibody",
                        "therapies",
                        "COVID-19",
                        "developing"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "biotech"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2020-08-13",
                "original_text": "Hexo Corp. (HEXO) to Post Q3 Earnings: What's in the Offing?",
                "features": {
                    "keywords": [
                        "Hexo",
                        "Corp.",
                        "Q3",
                        "Earnings"
                    ],
                    "sentiment_score": 0.5,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "cannabis",
                        "consumer goods"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2020-08-25",
                "original_text": "First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial",
                "features": {
                    "keywords": [
                        "Lilly",
                        "tirzepatide",
                        "cardiovascular",
                        "outcomes",
                        "trial"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare",
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            }
        ]
    ]
}